MarketWatch

Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist ...

The MarketWatch News Department was not involved in the creation of this content. Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of ...
MarketWatch

Tris Pharma to Debut Positive Results of Intranasal (Snorting) Human Abuse Potential Study of Cebranopadol, an Investigational First-In-Class Oral Dual-NMR Agonist for the ...

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced that the company will present intranasal human abusability data from cebranopadol, an investigational ...